论文部分内容阅读
目的:评价125I放射性粒子植入治疗纵隔区恶性肿瘤的临床价值。方法:回顾分析我院2008年12月至2010年5月间收治的18例经病理确诊为恶性纵隔肿瘤患者,接受包括125I放射性粒子植入治疗在内的综合治疗。术后1个月复查胸部CT进行近期疗效评价。结果:18例患者中肿瘤完全缓解10例,部分缓解5例,无变化2例,进展1例,总有效率83.3%(15/18)。随访18例,随访时间12～30个月。1年局部控制率88.9%(16/18)。结论:125I粒子穿刺植入治疗纵隔恶性肿瘤安全、可行,配合手术和(或)药物化疗,近期治疗效果满意。
Objective: To evaluate the clinical value of 125I radioactive seed implantation in the treatment of mediastinal malignant tumor. Methods: A retrospective analysis of our hospital from December 2008 to May 2010 admitted 18 cases of pathologically confirmed malignant mediastinal tumor patients, including 125I radioactive seed implantation treatment, including comprehensive treatment. A review of chest CT 1 month after surgery for short-term efficacy evaluation. Results: Of 18 patients, complete remission was achieved in 10 cases, partial remission in 5 cases, no change in 2 cases and progression in 1 case. The total effective rate was 83.3% (15/18). Follow-up 18 cases, followed up for 12 to 30 months. One-year local control rate of 88.9% (16/18). CONCLUSION: 125I seed implantation in the treatment of mediastinal malignant tumor is safe and feasible, with the surgical and (or) chemotherapy, the recent treatment is satisfactory.